Ablynx NV

General Information

(Note: “Our ordinary shares are listed on Euronext Brussels under the symbol “ABLX.” On October 13, 2017, the last reported sale price of our ordinary shares on Euronext Brussels was €16.24 per ordinary share, equivalent to a price of $19.08 per ADS, assuming an exchange rate of $1.179 per euro, the exchange rate as published by the European Central Bank on October 18, 2017.”)

We are a late-stage clinical biopharmaceutical company utilizing our proprietary Nanobody platform to develop treatments for a broad range of therapeutic indications with an unmet medical need. We believe that Nanobodies represent a leading next generation protein therapeutic technology. We have more than 45 proprietary and partnered Nanobody programs across a range of therapeutic indications including: hematology, inflammation, infectious disease, autoimmune disease, oncology and immuno-oncology.

Employees: 406
Founded: 2002
Contact Information
Address Technolgiepark 21, 9052 Ghent/Zwijnaarde, Belgium
Phone Number +32 9 262 00 00
Web Address http://www.ablynx.com
View Prospectus: Ablynx NV
Financial Information
Market Cap $1274.85mil
Revenues $78.1 mil (last 12 months)
Net Income $-58.4 mil (last 12 months)
IPO Profile
Symbol ABLX
Exchange NASDAQ
Shares (millions): 11.4
Price range $17.50 - $17.50
Est. $ Volume $200.0 mil
Manager / Joint Managers BofA Merrill Lynch/ J.P. Morgan/ Jefferies
CO-Managers Baird/ Bryan, Garnier/ Ladenburg Thalmann
Expected To Trade: 10/25/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change